Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
The products will be manufactured at the company's facility in Bengaluru
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
Subscribe To Our Newsletter & Stay Updated
